Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With

Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA)
for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200
mg/dL and

Submission for Indication Studied in the ANCHOR Phase 3 Clinical Trial Under
Special Protocol Assessment Agreement With FDA

BEDMINSTER, N.J. and DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today that the Food and Drug Administration
(FDA) has accepted its Supplemental New Drug Application (sNDA) seeking
approval for the marketing and sale of Vascepa^(R) (icosapent ethyl) capsules
for use as an adjunct to diet in the treatment of adult patients with high
triglycerides (TG ≥200 mg/dL and <500 mg/dL) with mixed dyslipidemia. The
acceptance of the sNDA indicates that the application is sufficiently complete
to permit a substantive review. The application will be subject to a standard
review and has been assigned a Prescription Drug User Fee Act (PDUFA) date of
December 20, 2013.The PDUFA date is the target date for the FDA to complete
its review of the sNDA.

"We are very pleased that the FDA has accepted our sNDA submission for the
ANCHOR indication, which supports the potential expansion of the Vascepa
patient population to include adult patients on statin therapy with
triglyceride levels ranging from 200 to 499 mg/dL and mixed dyslipidemia.We
estimate that one in five, or nearly 40 million, U.S. adults have triglyceride
levels ranging from 200 to 499 mg/dL," stated Joseph S. Zakrzewski, Chairman
and Chief Executive Officer of Amarin."The ANCHOR study showed that Vascepa
is unique in that it significantly lowered both triglycerides and
LDL-cholesterol on top of optimized statin therapy and exhibited a safety and
tolerability profile similar to placebo, unlike the clinical results of other
triglyceride-lowering therapies. If approved for the ANCHOR indication,
Vascepa will be the only approved prescription omega 3 therapy for
cardiovascular health management in this patient population (TG ≥200 mg/dL and
<500 mg/dL with mixed dyslipidemia) and will represent the next generation of
lipid management for potentially millions of patients."

About Vascepa®(icosapent ethyl) capsules

Vascepa®(icosapent ethyl) capsules, known in scientific literature as AMR101,
is a patented, pure-EPAomega-3 prescription product in a 1 gram capsule.

Indications and Usage

  *Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce
    triglyceride (TG) levels in adult patients with severe (≥500 mg/dL)
    hypertriglyceridemia.
  *The effect of Vascepa on the risk for pancreatitis and cardiovascular
    mortality and morbidity in patients with severe hypertriglyceridemia has
    not been determined.

Important Safety Information for Vascepa

  *Vascepa is contraindicated in patients with known hypersensitivity (e.g.,
    anaphylactic reaction) to Vascepa or any of its components and should be
    used with caution in patients with known hypersensitivity to fish and/or
    shellfish.
  *The most common reported adverse reaction (incidence >2% and greater than
    placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo).

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND ATWWW.VASCEPA.COM

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^(R) (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Forward-looking statements

This press release contains forward-looking statements, including statements
about regulatory submissions and the timing and potential for FDA review and
approval of such submissions, the efficacy and safety of Amarin's product
candidates and market opportunities for Vascepa and the clinical importance of
Vascepa. These forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. Among the factors that could
cause actual results to differ materially from those described or projected
herein include the following: uncertainties associated generally with research
and development, clinical trials and related regulatory reviews and approvals.
A further list and description of these risks, uncertainties and other risks
associated with an investment in Amarin can be found in Amarin's filings with
the U.S. Securities and Exchange Commission, including its most recent Annual
Report on Form 10-K. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date hereof. Amarin undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.

Vascepa has been approved for use by the FDA as an adjunct to diet to lower
triglyceride levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia.Vascepa is under various stages of development for
potential use in other indications that have not been approved by the
FDA.Nothing in this press release should be construed as marketing the use of
Vascepa in any indication that has not been approved by the FDA.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.